Navigation Links
StockCall Research on Boston Scientific and Medtronic: Focus on Paroxysmal Atrial Fibrillation
Date:1/22/2013

LONDON, January 22, 2013 /PRNewswire/ --

The medical appliances and equipment industry faced its fair share of challenges during the recession, as procedural volume in some cases was reduced due to the economic situation in the U.S. and Europe. Analysts from our services research team completed in-depth analysis on Boston Scientific Corporation (NYSE: BSX) and Medtronic Inc. (NYSE: MDT). These free reports are available at

http://www.stockcall.com/registration    

Competition also crimped margins for several companies, leading to lower sales and profits. However, with the recession in the rear view mirror, the outlook for the industry and companies such as Boston Scientific and Medtronic is positive. Now that companies have been afforded some breathing room, they are focusing their attentions on bringing new products to market and growing their international footprint. Download the free report on Scientific by signing up now at

http://www.StockCall.com/BSX012213.pdf

Both Boston Scientific and Medtronic [Free Report on MDT][1] have been looking to new products to grow their top- and bottom-lines, and both have recently been involved with paroxysmal atrial fibrillation. Atrial fibrillation affects around 15 million people globally, and can cause serious health problems such as strokes and heart failure.

In the case of Boston Scientific, the company newly announced that the first patient has been treated in its ZERO AF clinical trial. The results of the trial are anticipated to be used to back up an FDA regulatory submission for a paroxysmal atrial fibrillation indication.

Medtronic has also been busy, recently stating that the FDA has cleared the FlexCath Advance (TM) Steerable Sheath, an improvement to the Arctic Front Advance (TM) Cryoballon System. The new sheath will make it easier to reach inferior veins of the heart when delivering and positioning the cryoballoon catheter in the left atrium to treat paroxysmal atrial fibrillation.

Footer:

  1. Medtronic Inc. Technical Analysis [ http://www.StockCall.com/MedtronicInc012213.pdf ]

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com  


'/>"/>
SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation
2. Russian Government Starts Using Scopus for National Research Assessment
3. Breakthrough Research Could Create Sea Change in Global HIV Diagnosis: New Handheld Mobile Device Performs Laboratory-Quality HIV Testing
4. US Vitamin injections Posts New Research Involving B Vitamin Deficiency
5. Maximizing the Effectiveness of Market Research Groups through Outsourcing and Automation
6. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
7. BodyMedia Collaborates on Federal Health Research Study
8. Genomic Research Service Provider DNA Link Purchases 10 Ion Proton Sequencers
9. Fred Hutchinson Cancer Research Center Partners With GlaxoSmithKline to Develop Muscular Dystrophy Therapeutics
10. Seahorse Bioscience Announces Asia Mito 2012 Travel Award Winners Advancing Cell Metabolism Research
11. German Cancer Research Center Selects Contur ELN from Accelrys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
(Date:7/10/2017)... PARK, N.C. , July 10, 2017 ... $5m Convertible Note to support the development of CRISPR-Cas3 ... Tencent Holdings Limited, a leading Chinese Internet services provider, ... funding will advance multiple infectious disease product programs targeting ... Founded by Dr. Rodolphe ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
Breaking Medicine Technology:
(Date:7/20/2017)... Plainview, NY, July 20, 2017 (PRWEB) , ... ... ... Nastel Technologies, a global provider of enterprise-grade IT operations analytics and ... delivery arm of one of world’s largest healthcare services providers. , According ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... telemedicine platform, in which their iMedSecure™ comes included with each system installation. ... live images to remote participants for real-time collaboration and immediate decision-making requirements. ...
(Date:7/20/2017)... ... July 20, 2017 , ... Vixiar Medical, Inc. , ... systems for monitoring cardiopulmonary diseases, announced today that it has raised seed round ... submissions and fund final engineering and initial production of the Company’s first product, ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Dermatology Clinic announced today the addition of ... in Biology from LSU, graduating summa cum laude. He attended Emory University School of ... in St. Louis, Dr. Dunbar moved to New York to complete an AGCME-accredited Mohs ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... Business Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 is now available for ... this effort through Guild collaborative teams. , Non-members may download the Part ...
Breaking Medicine News(10 mins):